Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

The FDA has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular ...

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Susan Posner is recovering after receiving a life-saving gift from her nephew. She got his kidney decades after her brother donated one of his. “I feel like I ...

HAART is the acronym for "highly active antiretroviral therapy" used to treat HIV infection. The term HAART was coined in the late 1990s to describe the use of three or more antiretroviral drugs to ...

Vasculitis is a group of diseases, also known as angiitis, that damage blood vessels by causing inflammation. It can affect any blood vessel anywhere in the body. Vasculitis means inflammation of ...

A form of membranoproliferative glomerulonephritis, this ultra-rare disease affects roughly 2 to 3 out of every 1 million people. Because of damage to kidney glomeruli, people with C3G can ...